机构:[1]Department of Neurology, Beijing Institute for Brain Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China神经科系统神经内科首都医科大学宣武医院[2]Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, 11794 NY, USA[3]Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA
第一作者机构:[1]Department of Neurology, Beijing Institute for Brain Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China
通讯作者:
通讯机构:[2]Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, 11794 NY, USA[3]Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA
推荐引用方式(GB/T 7714):
Qi Zhifeng,Liu Ke Jian.Opportunities for Neuroprotective Drugs in the Era of Vascular Recanalization[J].TRANSLATIONAL STROKE RESEARCH.2024,15(2):333-334.doi:10.1007/s12975-023-01128-6.
APA:
Qi Zhifeng&Liu Ke Jian.(2024).Opportunities for Neuroprotective Drugs in the Era of Vascular Recanalization.TRANSLATIONAL STROKE RESEARCH,15,(2)
MLA:
Qi Zhifeng,et al."Opportunities for Neuroprotective Drugs in the Era of Vascular Recanalization".TRANSLATIONAL STROKE RESEARCH 15..2(2024):333-334